Quoin Pharmaceuticals, Ltd. — Form 8-K
Filed August 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
The 8-K discloses Item 5.02 (director/officer changes and compensation) and Item 5.07 (shareholder vote submission), but the actual text of these disclosures is not provided in the filing excerpt. No specific names, dollar amounts, dates, or details of changes are available from the document provided.
Why this rating
Filing flags director/officer changes but specifics absent. At $5.4M market cap, leadership changes could matter materially, but without details cannot assess severity or scope.
Extracted items
- 5.02 exec change
- 5.07 shareholder vote
- 8.01 other event
See more from August 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.